Evaluation of the DAS28 at week 14 or week 22 correlates best with long term attrition to infliximab therapy in rheumatoid arthritis patients

Cruyssen, B. Vander; Durez, Patrick; Van Looy, S.; Wijns, B.; Westhovens, Rene; Van den Bosch, F.; Mielants, H.; De Clerck, L.; Peretz, A.; Malaise, Michel; Verbruggen, L.; Vastesaeger, N.; Geldhof, A.; Boullart, L.; De Keyser, F.

Evaluation of the DAS28 at week 14 or week 22 correlates best with long term attrition to infliximab therapy in rheumatoid arthritis patients

Cruyssen, B. Vander

;

Durez, Patrick

;

Van Looy, S.

;

Wijns, B.

;

De Keyser, F.

;et.al.

(2006) Annual European Congress of Rheumatology (EULAR 2006) — Location: Amsterdam (Netherlands) (21.June.2006)

Files

No attached file found for this publication.

Details

Authors

Cruyssen, B. Vander
Author
Durez, PatrickUCLouvain
Author
Van Looy, S.
Author
Wijns, B.
Author
Westhovens, ReneUCLouvain
Author
De Keyser, F.
Author

Affiliations

Citations

APA
Chicago
FWB

Cruyssen, B. V., Durez, P., Van Looy, S., Wijns, B., Westhovens, R., Van den Bosch, F., Mielants, H., De Clerck, L., Peretz, A., Malaise, M., Verbruggen, L., Vastesaeger, N., Geldhof, A., Boullart, L., & De Keyser, F. (2006). Evaluation of the DAS28 at week 14 or week 22 correlates best with long term attrition to infliximab therapy in rheumatoid arthritis patients. Annals of the Rheumatic Diseases, 65, 114-115. https://hdl.handle.net/2078.5/148496 (Original work published 2006)